DAEWOONG PHARMA
Financials
Valuation Metrics
DAEWOONG PHARMA's Market Cap is ₩1.4T. At end of 2025 it was ₩2.0T. Ranked #248 of 2,436 in KR market (top 10%), #190 of 787 on KOSPI (top 24%), #26 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 11%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.43T KRW | KR#248/2,436 Sec#26/234 |
| Revenue | 1.59T KRW | KR#293/2,436 Sec#9/234 |
| Net Income | 198.64B KRW | KR#136/2,436 Sec#6/234 |
| Total Assets | 2.45T KRW | KR#261/2,436 Sec#9/234 |
| Net Assets | 1.15T KRW | KR#251/2,436 Sec#13/234 |
| Employees | 1,757 | KR#156/2,436 Sec#7/234 |
| Value | ||
| P/E | 7.21x | KR#493/2,436 Sec#22/234 |
| P/B | 1.24x | KR#1,671/2,436 Sec#115/234 |
| PEG | 0.25x | KR#565/2,436 Sec#33/234 |
| P/S | 0.90x | KR#1,316/2,436 Sec#72/234 |
| EV/EBITDA | 12.02x | KR#719/2,436 Sec#38/234 |
| FCF Yield | -2.96% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 17.21% | KR#180/2,436 Sec#11/234 |
| ROA | 8.11% | KR#334/2,436 Sec#26/234 |
| Op. Margin | 11.32% | KR#421/2,436 Sec#37/234 |
| Revenue Growth | 5.98% | KR#1,119/2,436 Sec#102/234 |
| Earnings Growth | 28.99% | KR#695/2,436 Sec#44/234 |
| Financial Health | ||
| Debt Ratio | 212.30% | KR#1,793/2,436 Sec#195/234 |
| Total Debt | 898.04B KRW | KR#210/2,436 Sec#6/234 |
| FCF | -42.33B KRW | KR#2,062/2,436 Sec#205/234 |
| Cash | 163.66B KRW | KR#318/2,436 Sec#14/234 |
| Current Ratio | 1.12x | KR#1,679/2,436 Sec#171/234 |
| Net Debt/EBITDA | 4.07x | KR#1,028/2,436 Sec#78/234 |
| Dividend | ||
| Div. Yield | 0.53% | KR#1,275/2,436 Sec#82/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -12.34% | KR#1,037/2,436 Sec#77/234 |
| 1M Return | -6.72% | KR#1,542/2,436 Sec#156/234 |
| From 52W High | -38.01% | KR#674/2,436 Sec#46/234 |
| 1Y MDD | -44.69% | KR#692/2,436 Sec#54/234 |
| Trading | ||
| Volume | 60,974 shares | KR#1,230/2,436 Sec#121/234 |
| Foreign Own. | 14.37% | KR#329/2,436 Sec#23/234 |
| Per Share | ||
| EPS | 17,249 KRW | KR#41/2,436 Sec#3/234 |
| BPS | 89,169 KRW | KR#146/2,436 Sec#8/234 |
Company Info
Daewoong Pharmaceutical was established in 2002 as a spin-off from Daewoong Co., Ltd., focusing on pharmaceutical manufacturing and sales. The company operates KGMP-compliant facilities in Hyangnam Industrial Complex, Hwaseong-si, and Osong Bio-Science Complex, Cheongju-si, producing key products like Nabota, Ursa, and Fexuclue. It is advancing global expansion with three innovative new drugs—Fexuclue, Envlo, and Nabota—pursuing a '1 Product, 1 Trillion Won' vision, and growing through digital healthcare investments and new drug development. It is headquartered in Hwaseong-si, Gyeonggi-do.